Overview
Non-Hodgkin’s lymphoma is a heterogeneous group of
lymphoproliferative malignancies formed by either B-cells or T-cell/natural
killer (NK) cells, as stated in the Introduction
section.
Non-Hodgkin’s lymphoma is the
11th most common neoplasm in the world. This
is the most common hematologic cancer. A detailed discussion about the
prevalence of non-Hodgkin’s lymphoma is in the Epidemiology
section.
Genetic aberrations and oncogenic viruses are the causes of
non-Hodgkin’s lymphoma that are listed in the Etiology
section.
The risk factors of non-Hodgkin’s lymphoma are enumerated in
the Risk Factors section.
The Classification section enumerates the different
classifications of non-Hodgkin’s lymphoma according to staging and histologic
types.
Non-Hodgkins Lymphoma_Disease SummaryHistory and Physical Examination
The Clinical Presentation section describes the signs and symptoms present in patients with non-Hodgkin’s lymphoma depending on the type and organ involvement. The Physical Examination section enumerates the expected findings in patients with non-Hodgkin’s lymphoma.
Diagnosis
Discussions on the different types of biopsies, molecular
and genetic analysis, laboratory examination, and other procedures are in the Laboratory Tests and Ancillaries section.
Imaging procedures that are helpful in the evaluation and
response to treatment in non-Hodgkin’s lymphoma are discussed in the Imaging section.
Other diseases that should be ruled out in
diagnosing non-Hodgkin’s lymphoma are listed in the Differential Diagnosis section.
Management
The Evaluation section provided useful prognostic
information that may be used to guide therapeutic decision-making in patients
with non-Hodgkin’s lymphoma.
The Pharmacological
Therapy section discusses in
detail the standard chemotherapeutic regimens, chemotherapeutic combinations,
alkylating agents, anti-CD19 chimeric antigen receptor T-cell therapy,
antimetabolites, monoclonal antibodies, bispecific antibody therapy agents, and
other anti-neoplastic and therapeutic agents in the treatment of non-Hodgkin’s
lymphoma. Supportive therapy is also discussed in this section.
The Nonpharmacological section includes other modalities such as
phototherapy and extracorporeal photopheresis in the management of
non-Hodgkin’s lymphoma. Observation or a “watch and wait” approach in the
management of non-Hodgkin’s lymphoma is also discussed in this section.
Bone marrow transplantation as a treatment option in
non-Hodgkin’s lymphoma is discussed in the Surgery section. Radiotherapy as another option in
the treatment of non-Hodgkin’s lymphoma is in the Radiation Therapy section.
The Prognosis
section discussed the importance of assessing the patient’s age, performance
status, serum LDH, clinical disease stage, and extranodal site involvement for
proper prognostication in patients with non-Hodgkin’s lymphoma.
